Inhibiting CA7: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: CA7

NCBI ID: G766

Content of Review Report on CA7 Target / Biomarker

CA7

Inhibiting CA7: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Carbonic anhydrase VII (CA7) is a protein that is expressed in various tissues throughout the body. It plays a crucial role in the regulation of cell signaling pathways, including the production of reactive oxygen species (ROS) that can cause damage to cellular components and Contribute to various diseases, such as cancer, neurodegenerative diseases, and systemic inflammatory diseases.

Recent studies have identified CA7 as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The CA7 protein has been shown to be involved in a variety of cellular processes that are relevant to these diseases, including the production of ROS, cell signaling pathways, and inflammation.

One of the key functions of CA7 is its role in the production of ROS. ROS are reactive oxygen species that can cause damage to cellular components and contribute to the development and progression of various diseases. CA7 has been shown to be involved in the production of ROS by participating in the redox reaction, which is a process that involves the transfer of electrons from one molecule to another.

In addition to its role in ROS production, CA7 is also involved in cell signaling pathways. It has been shown to be involved in the regulation of cell signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and inflammation.

Another function of CA7 is its role in inflammation. CA7 has been shown to be involved in the production of pro-inflammatory cytokines, such as TNF-伪, IL-1, and IL-6. These cytokines contribute to the development and progression of inflammatory diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The potential utility of CA7 as a drug target or biomarker comes from its ability to modulate the production of ROS, cell signaling pathways, and pro-inflammatory cytokines. This has led to the development of several compounds that have been shown to inhibit the activity of CA7 and its downstream targets, resulting in a reduction in the production of ROS and pro-inflammatory cytokines.

One of the most promising compounds that have been shown to inhibit the activity of CA7 is called NXR-1080. This compound is a small molecule that has been shown to inhibit the activity of CA7 and its downstream targets, including tyrosine phosphorylation and the production of ROS. NXR-1080 has also been shown to have anti-inflammatory effects and to have potential therapeutic applications in a variety of diseases.

Another compound that has been shown to inhibit the activity of CA7 is called FN-1034. This compound is a peptide that has been shown to inhibit the activity of CA7 and its downstream targets, including tyrosine phosphorylation and the production of ROS. has also been shown to have anti-inflammatory effects and to have potential therapeutic applications in a variety of diseases.

In conclusion, CA7 is a protein that is involved in a variety of cellular processes that are relevant to several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in ROS production, cell signaling pathways, and inflammation makes it a promising target for the development of new drugs or biomarkers. The inhibition of CA7 by compounds such as NXR-1080 and FN-1034 has the potential to lead to new therapeutic applications in a variety of diseases. Further research is needed to fully understand the role of CA7 as a drug target or biomarker and to develop effective therapies based on its properties.

Protein Name: Carbonic Anhydrase 7

Functions: Reversible hydration of carbon dioxide

The "CA7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CA7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets